AVANIR Pharmaceuticals Invites Investors to Rodman & Renshaw Techvest Healthcare Conference Webcast

SAN DIEGO--(BUSINESS WIRE)--Oct. 25, 2004--AVANIR Pharmaceuticals (AMEX: AVN) today announced that its presentation at the Rodman & Renshaw Techvest Healthcare Conference will be webcast live through the Company's website at http://www.avanir.com. President and Chief Executive Officer Dr. Gerald J. Yakatan will be presenting at 11:10 am Eastern time, on October 27th from the conference in New York.

The live webcast will be accessible through AVANIR's corporate website. To access the webcast, please log on to AVANIR's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software. An archived version of the presentation will be available for 90 days following the conference.

AVANIR Pharmaceuticals is a drug discovery and development company focused on the development of treatments for chronic diseases. The Company's lead product candidate, Neurodex(TM), recently completed a second pivotal Phase III trial for the treatment of pseudobulbar affect. Neurodex(TM) is also in Phase III clinical development for the treatment of neuropathic pain. An internally developed small molecule, AVP-13358, is in a Phase I clinical trial for the treatment of allergy and asthma. Preclinical programs include small molecule research in atherosclerosis and inflammation. AVANIR also develops human monoclonal antibodies for infectious diseases and other therapeutic applications. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect". The Company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

    CONTACT: AVANIR Pharmaceuticals
             Patrice Saxon, Investor Relations

    SOURCE: AVANIR Pharmaceuticals